Ergomed PLC
LSE:ERGO

Watchlist Manager
Ergomed PLC Logo
Ergomed PLC
LSE:ERGO
Watchlist
Price: 1 346 GBX Market Closed
Market Cap: 701.1m GBX
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
N/A
Revenue
Forecast
+5%
Operating Income
Forecast
N/A
Net Income
Forecast
+4%

Wall Street
Price Targets

ERGO Price Targets Summary
Ergomed PLC

There are no price targets for ERGO.
ERGO Lowest Forecast
Wall Street Target
Not Available
ERGO Average Forecast
Wall Street Target
Not Available
ERGO Highest Forecast
Wall Street Target
Not Available
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Ergomed PLC Competitors:
Price Targets
J
603127
Joinn Laboratories China Co Ltd
18% Upside
R
301333
R&G PharmaStudies Co Ltd
47% Upside
DIM
Sartorius Stedim Biotech SA
58% Upside
BANB
Bachem Holding AG
59% Upside
J
603127
Joinn Laboratories China Co Ltd
18% Upside
R
301333
R&G PharmaStudies Co Ltd
47% Upside
DIM
Sartorius Stedim Biotech SA
58% Upside
BANB
Bachem Holding AG
59% Upside
STVN
Stevanato Group SpA
25% Upside
CDXS
Codexis Inc
218% Upside
TMO
Thermo Fisher Scientific Inc
54% Upside
LONN
Lonza Group AG
27% Upside

Revenue
Forecast

Revenue Estimate
Ergomed PLC

For the last 8 years the compound annual growth rate for Ergomed PLC's revenue is 27%. The projected CAGR for the next 3 years is 11%.

27%
Past Growth
11%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Ergomed PLC

For the last 8 years the compound annual growth rate for Ergomed PLC's operating income is 40%. The projected CAGR for the next 3 years is 22%.

40%
Past Growth
22%
Estimated Growth
Estimates Accuracy
-13%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Ergomed PLC

For the last 8 years the compound annual growth rate for Ergomed PLC's net income is 50%. The projected CAGR for the next 3 years is 26%.

50%
Past Growth
26%
Estimated Growth
Estimates Accuracy
-29%
Average Miss
What are analyst estimates?

See Also

Summary
ERGO intrinsic value, competitors valuation, and company profile.
DCF Valuation
ERGO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ERGO stock valuation using valuation multiples.
Wall Street Estimates
ERGO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ERGO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ERGO's stock price target?
Not Available

ERGO doesn't have any price targets made by Wall Street professionals.

What is Ergomed PLC's Revenue forecast?
Projected CAGR
11%

For the last 8 years the compound annual growth rate for Ergomed PLC's revenue is 27%. The projected CAGR for the next 3 years is 11%.

What is Ergomed PLC's Operating Income forecast?
Projected CAGR
22%

For the last 8 years the compound annual growth rate for Ergomed PLC's operating income is 40%. The projected CAGR for the next 3 years is 22%.

What is Ergomed PLC's Net Income forecast?
Projected CAGR
26%

For the last 8 years the compound annual growth rate for Ergomed PLC's net income is 50%. The projected CAGR for the next 3 years is 26%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 246,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.